Sofovir-Daclahep (Sofosbuvir - Daclatasvir)

Sofovir (Sofovir) + Daclahep (Daclahep) are inhibitors for the treatment of chronic hepatitis C as a combination regimen of antiviral therapy in adult patients, either alone or in combination with other medicines.

Sofovir is a direct-acting antiviral agent that inhibits RNA-dependent
Hepatitis C virus NS5B polymerase required for virus replication.

Sofovir is available in the form of coated oval tablets, which dissolves exclusively in the environment of the stomach. Each tablet contains 400 mg of sofosbuvir.

A tangible therapeutic effect is observed due to the activity of the active substance called Sofosbuvir, which has a systemic effect in the body affected by hepatitis C.

COMPOSITION:

1 tablet Sofovir contains the active ingredient: sofosbuvir - 400 mg.

—————————

Daclahep (Daclahep) is an inhibitor of the viral (hepatitis C virus) NS5A protein, which is used to replicate the hepatitis C virus inside the liver cells (hepatocytes) and, thus, prevents the virus from entering infected blood from the hepatocytes. Through this action, it is possible to prevent the spread of the virus in the body.
Daclahep (daclatasvir) is a highly specific agent of direct action against the hepatitis C virus (HCV) and has no pronounced activity against other RNA and DNA containing viruses, including the human immunodeficiency virus (HIV).
Daclahep (Daclatasvir) is an inhibitor of non-structural protein 5A (NS5A), a multifunctional protein necessary for HCV replication, and thus inhibits two phases of the viral life cycle — viral RNA replication and virion assembly.

Based on in vitro data and computer simulation data, daclatasvir interacts with the N-terminus within domain 1 of the protein, which can cause structural distortions that hinder the realization of the functions of the NS5A protein.
It has been established that the drug is a powerful pan-genotypic inhibitor of the hepatitis C virus replication complex of genotypes 1a, 1b, 2a, 3a, 4a, 5a and 6a with values of effective concentration (50% reduction, EU 50) from picomolar to low nanomolar.

COMPOSITION:
1 tablet Daclahep contains the active ingredient: daclatasvir - 60 mg.